208 related articles for article (PubMed ID: 23940096)
1. The role of metabolic imaging in radiation therapy of prostate cancer.
Zhang VY; Westphalen A; Delos Santos L; Tabatabai ZL; Shinohara K; Vigneron DB; Kurhanewicz J
NMR Biomed; 2014 Jan; 27(1):100-11. PubMed ID: 23940096
[TBL] [Abstract][Full Text] [Related]
2. Correlation of phospholipid metabolites with prostate cancer pathologic grade, proliferative status and surgical stage - impact of tissue environment.
Keshari KR; Tsachres H; Iman R; Delos Santos L; Tabatabai ZL; Shinohara K; Vigneron DB; Kurhanewicz J
NMR Biomed; 2011 Jul; 24(6):691-9. PubMed ID: 21793074
[TBL] [Abstract][Full Text] [Related]
3. Multiparametric MRI in detection and staging of prostate cancer.
Boesen L
Dan Med J; 2017 Feb; 64(2):. PubMed ID: 28157066
[TBL] [Abstract][Full Text] [Related]
4. Metabolomic profiles of intact tissues reflect clinically relevant prostate cancer subtypes.
Dudka I; Lundquist K; Wikström P; Bergh A; Gröbner G
J Transl Med; 2023 Nov; 21(1):860. PubMed ID: 38012666
[TBL] [Abstract][Full Text] [Related]
5. Multiparametric MRI to improve detection of prostate cancer compared with transrectal ultrasound-guided prostate biopsy alone: the PROMIS study.
Brown LC; Ahmed HU; Faria R; El-Shater Bosaily A; Gabe R; Kaplan RS; Parmar M; Collaco-Moraes Y; Ward K; Hindley RG; Freeman A; Kirkham A; Oldroyd R; Parker C; Bott S; Burns-Cox N; Dudderidge T; Ghei M; Henderson A; Persad R; Rosario DJ; Shergill I; Winkler M; Soares M; Spackman E; Sculpher M; Emberton M
Health Technol Assess; 2018 Jul; 22(39):1-176. PubMed ID: 30040065
[TBL] [Abstract][Full Text] [Related]
6. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
7. Transrectal ultrasound-guided biopsy of prostate voxels identified as suspicious of malignancy on three-dimensional (1)H MR spectroscopic imaging in patients with abnormal digital rectal examination or raised prostate specific antigen level of 4-10 ng/ml.
Kumar V; Jagannathan NR; Kumar R; Thulkar S; Gupta SD; Hemal AK; Gupta NP
NMR Biomed; 2007 Feb; 20(1):11-20. PubMed ID: 16894640
[TBL] [Abstract][Full Text] [Related]
8. In vivo assessment of prostate cancer aggressiveness using magnetic resonance spectroscopic imaging at 3 T with an endorectal coil.
Kobus T; Hambrock T; Hulsbergen-van de Kaa CA; Wright AJ; Barentsz JO; Heerschap A; Scheenen TW
Eur Urol; 2011 Nov; 60(5):1074-80. PubMed ID: 21419565
[TBL] [Abstract][Full Text] [Related]
9. Spatially matched in vivo and ex vivo MR metabolic profiles of prostate cancer -- investigation of a correlation with Gleason score.
Selnaes KM; Gribbestad IS; Bertilsson H; Wright A; Angelsen A; Heerschap A; Tessem MB
NMR Biomed; 2013 May; 26(5):600-6. PubMed ID: 23280546
[TBL] [Abstract][Full Text] [Related]
10. The diagnostic accuracy and cost-effectiveness of magnetic resonance spectroscopy and enhanced magnetic resonance imaging techniques in aiding the localisation of prostate abnormalities for biopsy: a systematic review and economic evaluation.
Mowatt G; Scotland G; Boachie C; Cruickshank M; Ford JA; Fraser C; Kurban L; Lam TB; Padhani AR; Royle J; Scheenen TW; Tassie E
Health Technol Assess; 2013 May; 17(20):vii-xix, 1-281. PubMed ID: 23697373
[TBL] [Abstract][Full Text] [Related]
11. Spermine and citrate as metabolic biomarkers for assessing prostate cancer aggressiveness.
Giskeødegård GF; Bertilsson H; Selnæs KM; Wright AJ; Bathen TF; Viset T; Halgunset J; Angelsen A; Gribbestad IS; Tessem MB
PLoS One; 2013; 8(4):e62375. PubMed ID: 23626811
[TBL] [Abstract][Full Text] [Related]
12. Seminal plasma metabolomics reveals lysine and serine dysregulation as unique features distinguishing between prostate cancer tumors of Gleason grades 6 and 7.
Falegan OS; Jarvi K; Vogel HJ; Hyndman ME
Prostate; 2021 Aug; 81(11):713-720. PubMed ID: 34097313
[TBL] [Abstract][Full Text] [Related]
13. Prostate Cancer Risk Assessment in Biopsy-naïve Patients: The Rotterdam Prostate Cancer Risk Calculator in Multiparametric Magnetic Resonance Imaging-Transrectal Ultrasound (TRUS) Fusion Biopsy and Systematic TRUS Biopsy.
Mannaerts CK; Gayet M; Verbeek JF; Engelbrecht MRW; Savci-Heijink CD; Jager GJ; Gielens MPM; van der Linden H; Beerlage HP; de Reijke TM; Wijkstra H; Roobol MJ
Eur Urol Oncol; 2018 Jun; 1(2):109-117. PubMed ID: 31100233
[TBL] [Abstract][Full Text] [Related]
14. Magnetic Resonance Imaging-guided In-bore and Magnetic Resonance Imaging-transrectal Ultrasound Fusion Targeted Prostate Biopsies: An Adjusted Comparison of Clinically Significant Prostate Cancer Detection Rate.
Costa DN; Goldberg K; Leon AD; Lotan Y; Xi Y; Aziz M; Freifeld Y; Margulis V; Raj G; Roehrborn CG; Hornberger B; Desai N; Bagrodia A; Francis F; Pedrosa I; Cadeddu JA
Eur Urol Oncol; 2019 Jul; 2(4):397-404. PubMed ID: 31277776
[TBL] [Abstract][Full Text] [Related]
15. Risk-based Patient Selection for Magnetic Resonance Imaging-targeted Prostate Biopsy after Negative Transrectal Ultrasound-guided Random Biopsy Avoids Unnecessary Magnetic Resonance Imaging Scans.
Alberts AR; Schoots IG; Bokhorst LP; van Leenders GJ; Bangma CH; Roobol MJ
Eur Urol; 2016 Jun; 69(6):1129-34. PubMed ID: 26651990
[TBL] [Abstract][Full Text] [Related]
16. HR-MAS MR spectroscopy of breast cancer tissue obtained with core needle biopsy: correlation with prognostic factors.
Choi JS; Baek HM; Kim S; Kim MJ; Youk JH; Moon HJ; Kim EK; Han KH; Kim DH; Kim SI; Koo JS
PLoS One; 2012; 7(12):e51712. PubMed ID: 23272149
[TBL] [Abstract][Full Text] [Related]
17. Is there a role for ¹¹C-choline PET/CT in the early detection of metastatic disease in surgically treated prostate cancer patients with a mild PSA increase <1.5 ng/ml?
Castellucci P; Fuccio C; Rubello D; Schiavina R; Santi I; Nanni C; Allegri V; Montini GC; Ambrosini V; Boschi S; Martorana G; Marzola MC; Fanti S
Eur J Nucl Med Mol Imaging; 2011 Jan; 38(1):55-63. PubMed ID: 20848281
[TBL] [Abstract][Full Text] [Related]
18. Quantitative analysis of prostate metabolites using 1H HR-MAS spectroscopy.
Swanson MG; Zektzer AS; Tabatabai ZL; Simko J; Jarso S; Keshari KR; Schmitt L; Carroll PR; Shinohara K; Vigneron DB; Kurhanewicz J
Magn Reson Med; 2006 Jun; 55(6):1257-64. PubMed ID: 16685733
[TBL] [Abstract][Full Text] [Related]
19. Evaluating localized prostate cancer and identifying candidates for focal therapy.
Sartor AO; Hricak H; Wheeler TM; Coleman J; Penson DF; Carroll PR; Rubin MA; Scardino PT
Urology; 2008 Dec; 72(6 Suppl):S12-24. PubMed ID: 19095124
[TBL] [Abstract][Full Text] [Related]
20. p53 protein overexpression is associated with increased cell proliferation in patients with locally recurrent prostate carcinoma after radiation therapy.
Cheng L; Sebo TJ; Cheville JC; Pisansky TM; Slezak J; Bergstralh EJ; Pacelli A; Neumann RM; Zincke H; Bostwick DG
Cancer; 1999 Mar; 85(6):1293-9. PubMed ID: 10189134
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
